Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 11/20 | 0.50 |
| ▸ | MAOB | P27338 | 11/20 | 0.50 |
| ▸ | CASP3 | P42574 | 4/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PPOX | P50336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11725001 | 0.90 | MAOA (0.59) | MAOAMAOBPTGS2PPOX | |
| SCHEMBL9107678 | 0.81 | CES1 (0.55) | MAOAMAOB | |
| SCHEMBL2462070 | 0.81 | TGM2 (0.55) | MAOAMAOBCASP3 | |
| SCHEMBL29036115 | 0.80 | MCL1 (0.46) | MAOAMAOB | |
| SCHEMBL9680872 | 0.76 | MAOA (0.45) | MAOAMAOBPTGS2PPOX | |
| SCHEMBL11294862 | 0.75 | ELANE (0.55) | MAOACASP3 | |
| SCHEMBL9641876 | 0.74 | MAPT (0.55) | — | |
| SCHEMBL9811057 | 0.73 | ELANE (0.53) | MAOACASP3 | |
| SCHEMBL24721527 | 0.73 | MAOA (0.49) | MAOAMAOBPTGS2PPOX | |
| SCHEMBL27053415 | 0.72 | MAOA (0.53) | MAOAMAOBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAOA 2771/4885MAOB 2743/4885CASP3 816/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAOA 2771/4885MAOB 2743/4885CASP3 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.